For people with diabetes struggling to afford their insulin, new legislation in Congress could lead to lower pharmacy bills. A House bill introduced in March would allow the Food and Drug Administration to approve generic versions of medications called “biologics,” a class of complex drugs made using biotechnology. When the patent expires on a medicine manufactured by simpler chemical methods, a less expensive generic version may be produced. Not so for biologics, at least for now. One result is that no generic insulins are available. This bill, the Promoting Innovation and Access to Life-Saving Medicine Act, could change that. But the biotech industry is fighting the legislation, arguing that it would fail to assure that copycat biologics are safe and would weaken companies’ incentive to develop biotech medications.